Health TrialsbyHealthPanel

A Prospective Cohort Study on Drug-induced Liver Injury in China（DILI-P）

ConditionDrug-induced Liver Injury
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorDrug Induced Liver Disease Study Group

About this trial

This is a multi-center, prospective, non-interventional cohort study .

Its primary objectives are:

1. assess DILI patients' clinical characteristics, disease progression and influencing factors in clinical practice; 2. learn about suspected drug caused DILI,rechallenging, liver biochemical abnormalities mode, etc.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Diagnosis of DILI patients with various types and severity according to the 2015 version of the Chinese DILI treatment guidelines

RUCAM ≥6, or RUCAM between 3-5 is required by the three experts determined that the drug-induced liver injury

patient can provide informed consent form

Disqualifiers

non-drug-induced liver injury

Trial population

all patients with drug-induced liver injury

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

10,000 Participants
are grouped into 6 trial groups

6

Trial groups

See each trial group below.

Group A: cohort 1
Group B: cohort 2
Group C: cohort 3
Group D: cohort 4
Group E: cohort 5
Group F: cohort 6

Trial outcomes

Primary outcomes

1

Disease progression of DILI (drug-induced liver injury ), i.e. death, liver failure, chronic DILI, recover

Time frame
6 months

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Drug Induced Liver Disease Study Group

Lead sponsor

Source ClinicalTrials.gov
Apply now